|drug3583||Serologic immunoassays to SARS-CoV-2 antibodies Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
Clinical research focused to evaluate the effect as coadyuvant of a combination of L. plantarum and P. acidilactici in adults positive for SARS-CoV-2 with mild clinical COVID-19 symptoms. Main objective is to evaluate how this combination of probiotics reduce the risk to progress to moderate or severe COVID and associated advantages such as reduce the risk of death. Adittionnally this RCT is launching to explore the benefits of this combination of strains to modulate fecal microbiome and explore how this correlate with clinical improvement.
Description: Frequency of randomized subjects who progress from mild to moderate or severe COVID-19, as evaluated by WHO Clinical Progression ScaleMeasure: Severity progression of COVID-19 Time: 30 days
Description: Length of stay at Intensive care unitMeasure: Stay at ICU Time: 30 days
Description: Mortality ratio for all the causes related to COVID-19Measure: Mortality ratio Time: 30 days
Description: Frequency of lung abnormalities clasified by severity and measured by x-ray and artificial intelligenceMeasure: Lung abnormalities Time: 30 days
Description: Description of SARS-Cov-2 viral load evaluated by RT-PCR at screening and on days 15 and 30Measure: Viral load Time: 30 days
Description: Levels of Immunoglobulin G and Immunoglobulin M evaluated on day 15 and 30Measure: Levels of immunoglobulins Time: 30 days
Description: Frequency and severity of gastrointestinal manifestation evaluated by Gastrointestinal Symptom Rating Scale (GSRS)Measure: Gastrointestinal manifestations, where 0 means good health status and 5 worse status Time: 30 days
Description: Changes on fecal microbiome evaluated by 16S analysis on day 1st and 30thMeasure: Fecal microbiome Time: 30 days
Description: Frequency of adverse events reported on dairy report form after randomization and until day 30Measure: Adverse events Time: 30 days
Description: Change on C-reactive high sensitivity protein (hsCRP) and D-DimerMeasure: Change on Serum Biomarkers Time: Days 1st, 15th and 30th after randomization
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports